Eisai Inc. announced today that screening for global Study E2086-G000-202 (Study 202) to assess the efficacy, safety and ...

Cybin Inc (NASDAQ:HELP) is among the best psychedelic stocks to buy in 2026. Toronto, Canada-based Cybin Inc. is also known ...

Novo Nordisk A/S (NYSE:NVO) and The United Laboratories International Holdings Limited said Wednesday that their jointly ...

Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics ...

Abcuro, Inc., a clinical stage biotechnology company, today presented results at the 6th Global Conference on Myositis (GCOM) meeting, being held March 23-26, 2026 in Lisbon, Portugal from the Phase 2 ...

– Alixorexton is the First Oral Orexin 2 Receptor Agonist to Demonstrate Efficacy in a Large Phase 2 Study in Patients With Narcolepsy Type 2, Supporting Advancement to Phase 3 – – Alixorexton Met the ...

Upstream Bio Inc. UPB shares are up on Thursday following the company’s announcement of a Phase 3 development strategy for its treatment, verekitug. The company reported a cash position of $341.5 ...

The MARITIME Phase 3 Chronic Weight Management Studies are Actively Enrolling, and Phase 3 Studies in People Living With Atherosclerotic Cardiovascular Disease, Heart Failure and Obstructive Sleep ...

SynAct Pharma AB ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution, today announces that the first patients were dose ...

In this analysis, researchers aimed to quantify and bring attention to the time burden experienced by cancer patients enrolled in phase 2 clinical trials.

Study met primary endpoint, demonstrating statistically significant increase in the percentage of participants achieving EASI-75 at Week 16 across all doses tested, compared to placebo Tilrekimig ...